News articles about ContraVir Pharmaceuticals (NASDAQ:CTRV) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ContraVir Pharmaceuticals earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 43.4043983311085 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
Separately, Maxim Group set a $4.00 target price on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 30th.
ContraVir Pharmaceuticals (CTRV) traded down $0.02 during trading on Tuesday, hitting $0.44. 1,166,200 shares of the stock were exchanged, compared to its average volume of 933,991. ContraVir Pharmaceuticals has a 12-month low of $0.42 and a 12-month high of $2.14.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/05/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-contravir-pharmaceuticals-ctrv-stock-price.html.
ContraVir Pharmaceuticals Company Profile
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.